Phoenix Bio

MafF is an antiviral host factor that suppresses transcription from Hepatitis B Virus core promoter

2021/07/09

Marwa K. Ibrahim, Tawfeek H. Abdelhafez, Junko S. Takeuchi, Kosho Wakae, Masaya Sugiyama, Masataka Tsuge, Masahiko Ito, Koichi Watashi, Mohamed El. Kassas, Takanobu Kato, Asako Murayama, Tetsuro Suzuki, Kazuaki Chayama, Kunitada Shimotohno, Masamichi Muramatsu, Hussein H. Aly, Takaji Wakita

J Virol. 2021 Jul 12;95(15): e0076721. doi: 10.1128/JVI.00767-21. Epub 2021 Jul 12.

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

2021/07/09

Li, Y. Chen, L. Li, L. Sottas, C. Petrillo, S. K. Lazaris, A. Metrakos, P. Wu, H. Ishida, Y. Saito, T. Golden-Mason, L. Rosen, H. R. Wolff, J. J. Silvescu, C. I. Garza, S. Cheung, G. Huang, T. Fan, J. Culty, M. Stiles, B. Asahina, K. Papadopoulos, V.

iScience. 2021 May 1;24(5):102457. doi: 10.1016/j.isci.2021.102457.

Loss of lysophosphatidic acid receptor 1 in hepatocytes reduces steatosis via down-regulation of CD36

2021/07/09

Lua, I. Balog, S. Yanagi, A. Tateno, C. Asahina, K.

Prostaglandins Other Lipid Mediat. 2021 Jun 17:106577. doi: 10.1016/j.prostaglandins.2021.106577.

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice

2021/07/09

Ohya, K. Imamura, M. Teraoka, Y. Uchida, T. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Yamauchi, M. Kawaoka, T. Miki, D. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Song, H. Miyayama, Y. Hijikata, M. Chayama, K.

Biochem Biophys Res Commun. 2021 Jun 25;559:78-83. doi: 10.1016/j.bbrc.2021.04.062. Epub 2021 Apr 29.

Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers

2021/07/09

Yoshida, K. Doi, Y. Iwazaki, N. Yasuhara, H. Ikenaga, Y. Shimizu, H. Nakada, T. Watanabe, T. Tateno, C. Sanoh, S.Kotake, Y.

Clin Transl Sci. 2021 Jun 3. doi: 10.1111/cts.13070.

Coculture with hiPS-derived intestinal cells enhanced human hepatocyte functions in a pneumatic-pressure-driven two-organ microphysiological system

2021/06/17

Shinohara, M. Arakawa, H. Oda, Y. Shiraki, N. Sugiura, S. Nishiuchi, T. Satoh, T. Iino, K. Leo, S. Kato, Y. Araya, K. Kawanishi, T. Nakatsuji, T. Mitsuta, M. Inamura, K. Goto, T. Shinha, K. Nihei, W.
Sci Rep. 2021 Mar 8;11(1):5437. doi: 10.1038/s41598-021-84861-y.

Geranylgeranylacetone decreases the production of hepatitis B virus-related antigen by comprehensive downregulation of mRNA transcription activity

2021/06/17

Haraguchi, M. Miuma, S. Yamamoto, K. Nakao, Y. Ichikawa, T. Kanda, Y. Sasaki, R. Fukushima, M. Akazawa, Y. Miyaaki, H. Nakao, K.
J Gastroenterol Hepatol. 2021 Jan 4. doi: 10.1111/jgh.15394.

Cell-based high-throughput screening for the evaluation of reactive metabolite formation potential

2021/06/17

Harada, K. Kohara, H. Yukawa, T. Matsumiya, K. Shinozawa, T.
Toxicol In Vitro. 2021 Aug;74:105159. doi: 10.1016/j.tiv.2021.105159. Epub 2021 Apr 3.

Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model

2021/06/17

Dent, M. Hamorsky, K. Vausselin, T. Dubuisson, J. Miyata, Y. Morikawa, Y. Matoba, N.
Cell Mol Gastroenterol Hepatol. 2021;11(1):185-198. doi: 10.1016/j.jcmgh.2020.08.009. Epub 2020 Aug 27.

Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen

2021/06/17

Baudi, I. Isogawa, M. Moalli, F. Onishi, M. Kawashima, K. Ishida, Y. Tateno, C. Sato, Y. Harashima, H. Ito, H. Ishikawa, T. Wakita, T. Iannacone, M. Tanaka, Y.
PLoS Pathog. 2021 May 12;17(5):e1009228. doi: 10.1371/journal.ppat.1009228.

Understanding hepatitis B virus dynamics and the antiviral effect of interferon-alpha treatment in humanized chimeric mice

2021/06/17

Reinharz, V. Ishida, Y. Tsuge, M. Durso-Cain, K. Chung, T. L. Tateno, C. Perelson, A. S. Uprichard, S. L. Chayama, K. Dahari, H.
J Virol. 2021 Apr 28. pii: JVI.00492-20. doi: 10.1128/JVI.00492-20.

Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies

Ito, M. Takino, N. Nomura, T. Kan, A. Muramatsu, S. I.
Sci Rep. 2021 Apr 29;11(1):9322. doi: 10.1038/s41598-021-88614-9.

Identification of a novel long-acting 4′-modified nucleoside reverse transcriptase inhibitor against HBV

2021/06/17

Higashi-Kuwata, N. Hayashi, S. Kumamoto, H. Ogata-Aoki, H. Das, D. Venzon, D. Hattori, S. I. Bulut, H. Hashimoto, M. Otagiri, M. Takamune, N. Kishimoto, N. Davis, D. A. Misumi, S. Kakuni, M.
J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33843-5. doi: 10.1016/j.jhep.2020.12.006.

cccDNA_Pathway_Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation

2021/06/17

Luo, J. Luckenbaugh, L. Hu, H. Yan, Z. Gao, L. Hu, J.
mBio. 2020 Feb 18;11(1):e03423-19. doi: 10.1128/mBio.03423-19.

PXBマウス関連の学術論文のご紹介:南カリフォルニア大学

2021/06/08

弊社の共同研究先である南カリフォルニア大学より、PXBマウス・PXB-cells関連の学術論文が発表されましたので
ご紹介申し上げます。

【詳細】
掲載雑誌名:iScience. 2021 May 1;24(5):102457. (PMID: 34013171)
論文名:Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty

liver disease

著者:Dr. Yuchang Li, et. al.(University of Southern California)
概要:
University of Southern CaliforniaのVassilios Papadopoulosらの研究グループは、弊社との共同研究の成果として、非アルコール性脂肪性肝疾患(NAFLD)における、Tranlocator protein(TSPO)の機能に関する論文をiScienceに発表致しました。これまでに脂肪肝から肝硬変へと病態が進行するに伴い、TSPOの発現量が増加することが知られていましたが、その機能は全く分かっていませんでした。今回の論文では、弊社で作成されたPXBマウス由来の新鮮肝細胞であるPXB-cellsや、肝がん由来培養細胞、TSPOノックアウトラットなどを用いて、TSPOは肝細胞におけるコレステロール合成や、それに伴う小胞体ストレス、胆汁酸合成経路の調節による繊維化の制御に関わる等、様々な役割を果たしている事などが明らかにされました。先進国を中心に、世界中で4人に1人が罹患していると推定されているNAFLDの病理メカニズムの解明につながる、重要な研究成果であると考えられます。

URL:https://pubmed.ncbi.nlm.nih.gov/34013171/

PXBマウス・PXB-cells関連の学術論文のご紹介:自治医科大学

2021/05/19

自治医科大学(村松慎一先生の研究グループ)より、PXBマウス・PXB-cells関連の学術論文が
発表されましたのでご紹介申し上げます。

【詳細】
掲載雑誌名:nature Sci Rep. 2021 Apr 29;11(1):9322. doi: 10.1038/s41598-021-88614-9.P
論文名:Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
著者:Dr. Mika Ito, et. al.(自治医科大学)
URL:https://pubmed.ncbi.nlm.nih.gov/33927271/

Dual Agonist of Farnesoid X Receptor and G Protein-coupled Receptor TGR5 Inhibits Hepatitis B Virus Infection in Vitro and in Vivo

2021/03/04

Ito, K. Okumura, A. S. Takeuchi J Watashi, K. Inoue, R. Yamauchi, T. Sakamoto, K. Yamashita, Y. Iguchi, Y. Une, M. Wakita, T. Umezawa, K. Yoneda, M.

Hepatology. 2021 Jan 12. doi: 10.1002/hep.31712.

Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes

2021/03/04

Sooyoung Lee, Ashish Goyal, Alan S. Perelson, Yuji Ishida, Takeshi Saito, Michael Gale, Jr.

iScience. 2021 Jan 4;24(1):101969. doi: 10.1016/j.isci.2020.101969. eCollection 2021 Jan 22.

Evaluation of the Utility of PXB Chimeric Mice for Predicting Human Liver Partitioning of Hepatic Organic Anion-Transporting Polypeptide Transporter Substrates

2021/03/04

Feng, B. Pemberton, R. Dworakowski, W. Ye, Z. Zetterberg, C. Wang, G. Morikawa, Y. Kumar, S.

Drug Metab Dispos. 2021 Mar;49(3):254-264. doi: 10.1124/dmd.120.000276. Epub 2020 Dec 29.

PXB-cells, fresh primary hepatocytes from humanized mouse livers, exhibit nonalcoholic fatty liver like properties, including large very low density lipoprotein

2021/03/04

Sayaka Tomatsu 1, Masaki Takahashi 2, Masakazu Kakuni 2, Gen Toshima 3, Fumiko Kimura 3, Junichiro Takahashi 3, Yui Umekawa 1, Akira Sasaki 1, Keishi Hata

J. Biol. Macromol., 21 (1), 51-52 (2021)